Drop in biological initiation for patients with psoriasis during the COVID-19 pandemic.
作者信息
Penso L, Dray-Spira R, Weill A, Zureik M, Sbidian E
机构信息
GIS-EPIPHARE, Groupement d'intérêt scientifique Epidémiologie des produits de santé ANSM-CNAM, Paris, F-75020, France.
Université Paris-Est Creteil, EpiDermE, Créteil, F-94010, France.
出版信息
Br J Dermatol. 2021 Sep;185(3):671-673. doi: 10.1111/bjd.20406. Epub 2021 Jun 14.
Abstract
摘要
相似文献
1
Drop in biological initiation for patients with psoriasis during the COVID-19 pandemic.新冠疫情期间银屑病患者生物制剂起始治疗率下降。
Br J Dermatol. 2021 Sep;185(3):671-673. doi: 10.1111/bjd.20406. Epub 2021 Jun 14.
2
Clinical management of psoriasis patients during the COVID-19 pandemic.COVID-19 大流行期间银屑病患者的临床管理。
J Dermatolog Treat. 2022 Mar;33(2):1166-1167. doi: 10.1080/09546634.2020.1781045. Epub 2020 Jun 22.
3
Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?在新冠疫情期间，化脓性汗腺炎的生物治疗与银屑病的生物治疗有何不同？
J Dermatolog Treat. 2022 Feb;33(1):599. doi: 10.1080/09546634.2020.1771256. Epub 2020 Jun 19.
4
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.2019年冠状病毒病大流行对接受生物疗法治疗的慢性斑块状银屑病患者的影响：意大利北部的经验。
Br J Dermatol. 2020 Aug;183(2):373-374. doi: 10.1111/bjd.19158. Epub 2020 May 28.
5
Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.COVID-19 大流行期间生物治疗的银屑病患者监测：单中心经验。
Dermatol Ther. 2021 Jan;34(1):e14700. doi: 10.1111/dth.14700. Epub 2020 Dec 28.
6
Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis [Formula: see text].严重急性呼吸综合征冠状病毒 2 与银屑病患者生物制剂的使用 [公式：见正文]。
J Cutan Med Surg. 2020 Nov/Dec;24(6):625-632. doi: 10.1177/1203475420945234. Epub 2020 Aug 6.
7
Reply: "Biologics for psoriasis during COVID-19 outbreak".回复：“新冠疫情期间用于银屑病的生物制剂”
J Am Acad Dermatol. 2020 Jun;82(6):e217-e218. doi: 10.1016/j.jaad.2020.04.004. Epub 2020 Apr 10.
8
Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.2019 冠状病毒病大流行期间用于炎症性皮肤病的生物制剂的单中心调查。
J Dermatol. 2021 Dec;48(12):1907-1912. doi: 10.1111/1346-8138.16159. Epub 2021 Sep 21.
9
Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China.新冠疫情期间生物制剂治疗银屑病患者的安全性：来自中国武汉的经验
Eur J Dermatol. 2020 Dec 1;30(6):738-740. doi: 10.1684/ejd.2020.3908.
10
Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course.在 COVID-19 大流行早期使用生物制剂治疗银屑病：一项研究调查了患者对治疗和疾病过程的态度。
J Cosmet Dermatol. 2021 Oct;20(10):3098-3102. doi: 10.1111/jocd.14381. Epub 2021 Aug 8.
引用本文的文献
1
Enhanced impact of psoriasis severity on the treatment demands of patients during the COVID-19 pandemic: a cross-sectional study based on a national psoriasis registry in China.银屑病严重程度对 COVID-19 大流行期间患者治疗需求的影响增强：基于中国全国银屑病登记处的一项横断面研究。
BMJ Open. 2024 Feb 17;14(2):e079627. doi: 10.1136/bmjopen-2023-079627.
2
A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: Focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting.一项关于探究2019冠状病毒病（COVID-19）与银屑病相互影响的系统评价和荟萃分析：聚焦银屑病患者的COVID-19病程及在此背景下对生物制剂的看法。
Immun Inflamm Dis. 2023 Nov;11(11):e1063. doi: 10.1002/iid3.1063.
3
Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines.法国在 COVID-19 大流行期间和为 COVID-19 疫苗全国药物流行病学监测进行的真实研究的贡献。
Therapie. 2023 Sep-Oct;78(5):553-557. doi: 10.1016/j.therap.2022.12.013. Epub 2023 Jan 20.
4
Impact of coronavirus disease 2019 on contraception use in France.2019 冠状病毒病对法国避孕措施使用的影响。
Therapie. 2023 Sep-Oct;78(5):593-603. doi: 10.1016/j.therap.2023.01.002. Epub 2023 Jan 20.
5
Effect of COVID-19 pandemic on psoriatic patients dermatology admissions and biologic treatment adherences: A single-center retrospective study.2019年冠状病毒病大流行对银屑病患者皮肤科住院及生物治疗依从性的影响：一项单中心回顾性研究。
J Cosmet Dermatol. 2021 Nov;20(11):3362-3363. doi: 10.1111/jocd.14512. Epub 2021 Oct 11.
6
Clinical Dermatology and COVID-19 Pandemic: Narrative Review.临床皮肤病学与新冠疫情：叙述性综述
Indian J Dermatol. 2021 May-Jun;66(3):246-255. doi: 10.4103/ijd.ijd_463_21.
7
Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France.银屑病相关治疗暴露与 COVID-19 大流行第一波和第二波期间的住院或院内死亡率：法国 1326312 例患者的队列研究。
Br J Dermatol. 2022 Jan;186(1):59-68. doi: 10.1111/bjd.20659. Epub 2021 Aug 31.
本文引用的文献
1
The impact of the coronavirus disease (COVID-19) pandemic on outpatient epilepsy care: An analysis of physician practices in Germany.冠状病毒病（COVID-19）大流行对门诊癫痫治疗的影响：德国医生实践分析。
Epilepsy Behav. 2021 Apr;117:107833. doi: 10.1016/j.yebeh.2021.107833. Epub 2021 Feb 19.
2
The impact of COVID-19 on systemic anticancer treatment delivery in Scotland.COVID-19 对苏格兰系统抗癌治疗的影响。
Br J Cancer. 2021 Apr;124(8):1353-1356. doi: 10.1038/s41416-021-01262-8. Epub 2021 Feb 2.
3
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.与银屑病患者 COVID-19 不良结局相关的因素：一项基于全球注册研究的分析。
J Allergy Clin Immunol. 2021 Jan;147(1):60-71. doi: 10.1016/j.jaci.2020.10.007. Epub 2020 Oct 16.
4
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
5
Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).英夫利昔单抗与英国和爱尔兰银屑病患者严重感染风险增加相关：英国皮肤科医师协会生物干预注册处（BADBIR）的结果。
Br J Dermatol. 2019 Feb;180(2):329-337. doi: 10.1111/bjd.17036. Epub 2018 Oct 21.
6
Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM).银屑病患者使用生物制剂治疗的持续性：来自法国国家健康保险数据库（SNIIRAM）的 16545 名生物制剂初治患者的真实世界分析。
Br J Dermatol. 2019 Jan;180(1):86-93. doi: 10.1111/bjd.16809. Epub 2018 Sep 23.
7
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.与经典系统药物相比，接受生物药物治疗的中重度银屑病患者的感染情况：来自 BIOBADADERM 登记处的研究结果。
J Invest Dermatol. 2017 Feb;137(2):313-321. doi: 10.1016/j.jid.2016.08.034. Epub 2016 Sep 25.
Zotero 插件